Login
$ORMP
$3.90 +$0.19 (5.12%) Live

$ORMP 8-K SEC Filings

Filed On Filing
17 Sep 2026 8-K: Submission of Matters to a Vote of Security Holders

On September 15, 2026, the Company held its 2026 Annual Meeting of Stockholders. The final voting results at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) are set forth below.

30 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events

1. The location of the registered office of the Corporation, and the name of its registered agent, shall be as set forth in the Certificate of Incorporation.

31 Mar 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets

As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on January 14, 2026 (the “Prior 8-K”), on January 12, 2026, Oramed Pharmaceuticals Inc. (the “Company”) entered into tha...

20 Feb 2026 8-K: Entry into a Material Definitive Agreement

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURIT...

14 Jan 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of January 12, 2026, by and among Lifeward Ltd., a company limited by shares organized under the laws of the State of Israel (“Parent”), Oratech Pharma, Inc., a...

07 Jan 2026 8-K: Other Events

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

31 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On December 31, 2025, the board of directors (the “Board”) of Oramed Pharmaceuticals Inc. (the “Company”) received notice of Leonard Sank’s intention to resign from the Board, effective as of January 1, 2026. Mr. Sank’s resignation did n...

31 Dec 2025 8-K: Other Events

As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 23, 2025, on July 22, 2025, Oramed Pharmaceuticals Inc. (the “Company”) entered into an Option Agreement for the Repurcha...

17 Nov 2025 8-K: Results of Operations and Financial Condition

NEW YORK, November 17, 2025 -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial re...

17 Nov 2025 8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders

Rights Agreement, dated as of November 17, 2025 (“Agreement”), between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, as Rights Agent (the “Rights Agent”).

24 Oct 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

SHARE REPURCHASE AGREEMENT (this “Agreement”) dated as of October 20, 2025, between Hefei Tianhui Biotech Co., Ltd. (“Seller”) and Oramed Pharmaceuticals Inc. (“Repurchaser”).

06 Oct 2025 8-K: Other Events

As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 23, 2025, on July 22, 2025, Oramed Pharmaceuticals Inc. (the “Company”) entered into an Option Agreement for the Repurcha...

21 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

On August 19, 2025, Oramed Pharmaceuticals Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders. At the 2025 Annual Meeting of Stockholders, the Company’s stockholders approved an amendment of the Company’s Amended and Resta...

23 Jul 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Certain information in this document (indicated by [***]) has been excluded pursuant to Regulation S-K Item 601(b)(10). Such information is not material and is treated by the Registrant as private or confidential.

21 May 2025 8-K: Other Events

On May 21, 2025, Oramed Pharmaceuticals Inc. (the “Company”) announced that its Board of Directors authorized a one-year extension of the Company’s current stock buyback program, which was set to expire in June 2025, pursuant to which th...

28 Apr 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This Share Purchase Agreement (this “Agreement”) is dated as of April 24, 2025, between Alpha Tau Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pag...

03 Mar 2025 8-K: Entry into a Material Definitive Agreement

This PURCHASE AND SALE AGREEMENT (this “Agreement”), dated as of February 28, 2025, is by and among SCILEX PHARMACEUTICALS INC., a Delaware corporation (the “Seller”), SCILEX HOLDING COMPANY, a Delaware corporation (the “Seller Parent”, ...

27 Feb 2025 8-K: Entry into a Material Definitive Agreement

This LIDOCAINE LICENSE AGREEMENT (this “Agreement”), dated as of February 22, 2025 (the “Effective Date”), is by and between SCILEX PHARMACEUTICALS INC., a Delaware corporation (“Licensor”), and ROYALTYVEST LTD., a British Virgin Islands...

11 Feb 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This Ancillary Agreement Completion Protocol and Supplemental Agreement (this “Agreement”) is entered into as of February 7, 2025 (the “Effective Date”) by and among

22 Jan 2025 8-K: Entry into a Material Definitive Agreement

RE: Amendment to Senior Secured Promissory Note (this “Amendment”)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support